glp 1 agonists with cardiovascular benefit agonist risks GLP-1 receptor agonist-based therapies and risk: a review of The cardiovascular effects of GLP-1

Diabetes 67 , 522P (2018) A.B

In a clinical trial, combination therapy with liraglutide and metformin shows significantly greater weight loss and lower incidence of hypoglycaemia, as compared to combination therapy with glimepiride and metformin 12,13

The Genentech / Roche Group-backed drug GAZYVA (obinutuzumab) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with active Lupus Nephritis (LN) who are on standard therapy

Farxiga side effects Because Farxiga primarily removes glucose through the urine, it can lead to urinary tract infections (approximately 9% of Farxiga users) and genital yeast infections due to increased sugar in the urinary tract

GLP-1RA essentials in gastroenterology: side effect management, precautions for endoscopy and applications for gastrointestinal disease treatment